Literature DB >> 15238207

Chronic Intestinal Pseudoobstruction.

Greg Lyford1, Amy Foxx-Orenstein.   

Abstract

Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.

Entities:  

Year:  2004        PMID: 15238207     DOI: 10.1007/s11938-004-0018-0

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  25 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion.

Authors:  A E Foxx-Orenstein; J G Jin; J R Grider
Journal:  Am J Physiol       Date:  1998-11

Review 3.  Chronic intestinal pseudo-obstruction syndromes.

Authors:  M D Schuffler
Journal:  Med Clin North Am       Date:  1981-11       Impact factor: 5.456

4.  Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction.

Authors:  T Minami; H Nishibayashi; Y Shinomura; Y Matsuzawa
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

5.  Current results of intestinal transplantation. The International Intestinal Transplant Registry.

Authors:  D Grant
Journal:  Lancet       Date:  1996-06-29       Impact factor: 79.321

Review 6.  Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome.

Authors:  N Sodhi; M Camilleri; J K Camoriano; P A Low; R D Fealey; M C Perry
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

7.  Antroduodenal motility in children with chronic intestinal pseudo-obstruction.

Authors:  P E Hyman; S V McDiarmid; J Napolitano; C E Abrams; T Tomomasa
Journal:  J Pediatr       Date:  1988-06       Impact factor: 4.406

8.  Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover, placebo-controlled trial.

Authors:  C Di Lorenzo; S N Reddy; J Villanueva-Meyer; I Mena; S Martin; P E Hyman
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

9.  The surgeon's role in the treatment of chronic intestinal pseudoobstruction.

Authors:  M M Murr; M G Sarr; M Camilleri
Journal:  Am J Gastroenterol       Date:  1995-12       Impact factor: 10.864

10.  Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.

Authors:  M Camilleri; R K Balm; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

View more
  6 in total

Review 1.  Chronic intestinal pseudo-obstruction.

Authors:  Alexandra Antonucci; Lucia Fronzoni; Laura Cogliandro; Rosanna-F Cogliandro; Carla Caputo; Roberto De Giorgio; Francesca Pallotti; Giovanni Barbara; Roberto Corinaldesi; Vincenzo Stanghellini
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 2.  Building a second brain in the bowel.

Authors:  Marina Avetisyan; Ellen Merrick Schill; Robert O Heuckeroth
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

3.  TGFβR-1/ALK5 inhibitor RepSox induces enteric glia-to-neuron transition and influences gastrointestinal mobility in adult mice.

Authors:  Chang-Jie Shi; Jun-Jiang Lian; Bo-Wen Zhang; Jia-Xue Cha; Qiu-Hong Hua; Xiao-Ping Pi; Yu-Jun Hou; Xin Xie; Ru Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-07-06       Impact factor: 6.150

4.  Repetitive Colonoscopic Decompression as a Bridge Therapy before Surgery in a Pregnant Patient with Chronic Intestinal Pseudo-Obstruction.

Authors:  Joon Sung Kim; Bo-In Lee; Byung-Wook Kim; Hwang Choi; Yun-Seok Lee; Leeso Maeng
Journal:  Clin Endosc       Date:  2013-09-30

5.  A Novel Approach to the Symptomatic Management of Chronic Megacolon.

Authors:  Michelle J Ward
Journal:  Case Rep Surg       Date:  2021-01-25

Review 6.  Latest developments in chronic intestinal pseudo-obstruction.

Authors:  Chang-Zhen Zhu; Hong-Wei Zhao; Hong-Wei Lin; Feng Wang; Yuan-Xin Li
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.